Table 1: Summary of the CD8 T cell responses to the Sp17 peptides by DLBCL patients.

PatientsDiagnosisHLA statusPattern of Sp17 staining-IFN response to peptides per 50,000 cells
Sp17(1)Sp17(2)Sp17(3)No peptideHIV-1PHA

Significant response
1DLBCL(dn)Cytoplasm and <10% nuclei
2DLBCL(dn)Scattered nuclei
5DLBCL(dn)
7DLBCL(dn)<10% nuclei
8DLBCL(dn)ND
9DLBCL(dn)
12DLBCL(dn)Weak cytoplasm and < 5% nuclei
14DLBCL(dn)ND
18DLBCL(dn)Weak cytoplasm and <5% nuclei
19DLBCL(t)<10% nuclei
21DLBCL(dn)Cytoplasm + scattered < 5% nuclei
22DLBCL(t)ND
37DLBCL(dn)<5% nuclei
39T cell rich
No significant response
3DLBCL(dn)0201+
4DLBCL(dn)0201+
6DLBCL(dn)0201+
10DLBCL(dn)0101+ND
11DLBCL(dn)0201+ND
13DLBCL(dn)0201+
15DLBCL(dn)0101+ND
16DLBCL(dn)0201+
17DLBCL(dn)0201+ND
20DLBCL(dn)0101+Cytoplasm + scattered < 5% nuclei
38DLBCL(dn)0201+ND
40DLBCL(dn)0201-negative, 0101-negativeND
41DLBCL(dn)0201-negative, 0101-negative
42DLBCL(dn)0201-negative, 0101-negativeND
43DLBCL(dn)0201-negative, 0101-negative>500
48DLBCL(dn)0201-negative, 0101-negative
49DLBCL(dn)0201-negative, 0101-negativeND
Healthy donors
10201+ND
20201+ND
30201+ND
40301+ND

DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant -IFN responses are highlighted in bold. ND, not determined.